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Background: The p.Leu1077Pro CFTR mutation was firstly described in 1992 as a mild allele that confers a
pancreatic sufficiency phenotype but the information collected in database CFTR2 lead to consider p.Leu1077Pro as
a severe CF mutation. Although it is typical of Southern Italy, p.Leu1077Pro is not included in the mutation panel
firstly tested in individuals originated from this area. The aim of our study was to describe prevalence and clinical
features in patients bearing this mutation followed in our Cystic Fibrosis Centre to demonstrate that this mutation
should be included in the mutation panel firstly tested in patients originated from Southern Italy.
Findings: We reviewed data from a cohort of 111 cystic fibrosis patients. 4 patients who were heterozygous for the
p.Leu1077Pro mutation were included in the study.
In our Cystic Fibrosis Centre, the prevalence of p.Leu1077Pro is 3.6% among all mutations. All patients had positive
sweat test values, pancreatic insufficiency and pulmonary exacerbations. One out of four patients even showed
both FEV1 and FVC values significantly below the normal range, the presence of bronchiectasis and chronic
Pseudomonas aeruginosa colonization.
Conclusions: We found that the p.Leu1077Pro CFTR mutation is associated with a classic CF phenotype confirming
what is reported in CFTR2 database. The relatively high prevalence of p.Leu1077Pro associated with the severe
clinical course of the disease in patients bearing this mutation is of interest for genetic counselling purposes, as it
should be part of mutation panel to be tested in individuals originated from Southern Italy.
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Cystic fibrosis (CF) is the most common life-shortening
monogenic genetic disease in Caucasians. It is caused by
mutations in the cystic fibrosis transmembrane conduct-
ance regulator (CFTR) gene [NCBI Reference Sequence:
NM_000492.3] [1]. There are more than 1900 mutations
in CFTR and the most prevalent mutation results in dele-
tion of phenylalanine at position 508 (p.Phe508del) [2].
There is a correlation between the general type of CFTR
mutation and disease phenotype, so the disease severity, to
some extent, correlates with organ’s sensitivity to CFTR
dysfunction and with the amount of functional protein.
Specifically, patients who carry class I-III mutations on
both alleles are associated with pancreatic exocrine insuffi-
ciency (PI), whereas those carrying at least one class IV-VI* Correspondence: leonardi@unict.it
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reproduction in any medium, provided the orCFTR mutation are associated with pancreatic sufficiency
(PS). These correlations are not absolute and some muta-
tions may be associated with either pancreatic sufficiency
or insufficiency [3]. The classic CF phenotype include
pathological sweat test, multi-organ involvement with pre-
dominant severe respiratory disease, pancreatic insuffi-
ciency and male infertility [4,5]. About 10% of patients
present a mild form of CF often involving a single organ
dysfunction, in many cases with mild respiratory symp-
toms, pancreatic sufficiency and normal or borderline
sweat test [6,7].
The p.Leu1077Pro (L1077P) mutation consists in a tran-
sition T to C at nucleotide position 3362 in exon 17b of
CFTR cDNA that is responsible of change of Leucine
(CTG) to Proline (CCG) at position 1077 of the protein.
This mutation belongs to the class III CFTR mutations
and produce a protein that is trafficked to the cell mem-
brane but does not respond to cAMP stimulation [8].d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phenotype in patients carrying another CFTR mutation
with no residual function [3] but Bozon et al. [8] firstly
found evidence that the p.Leu1077Pro was associated
with a pancreatic sufficiency even if their study did not
contain functional data.
The information collected in database CFTR2 [9],
analyzing data from 40 patients with this mutation, lead
to consider p.Leu1077Pro as a severe CF mutation, as-
sociated with PI in 78% of patients and Pseudomonas
Aeruginosa infection in 55% of patients.
Although this mutation is typical of Southern Italy, as
evidenced by Castaldo et al. [10] and although it should
be predictive of a severe CF phenotype, p.Leu1077Pro is
not included in the mutation panel firstly tested in indi-
viduals originated from this area since the information
collected in CFTR2 are only available from 2011, and
the only information held prior to the creation of this
database were related to the work of Bozon et al.
The aim of our study was therefore to describe preva-
lence and clinical features in Sicilian patients bearing
the p.Leu1077Pro CFTR mutation followed in our Cystic
Fibrosis Centre to add new data on this issue.
Findings
Patients population
We reviewed data from a cohort of 111 Sicilian patients
with a diagnosis of cystic fibrosis followed in the Cystic
Fibrosis Centre of the Catania University Hospital (Eastern
Sicily - Southern Italy). All patients were followed in the
centre since the time of the diagnosis. Sweat test, clinical
data and genotypes were available for all the patients. Four
patients (3 males, age range 7 – 20 years) who were het-
erozygous for the p.Leu1077Pro mutation were included
in the study: three patients also carried the p.Phe508del
(ΔF508) mutation in the second allele while one carried
the p.Asn1303Lys (N1303K) mutation. The group in-
cluded one adult, one adolescent and two children.
Demographic data of the patients are shown in
Table 1.
Three out of four patients, who were born after 1998,
were screened for CF. They had abnormal IRT values
and for this reason the CF diagnosis was made soon
after birth by sweat chloride values (>60 mmol/l). In theTable 1 Demographic data of the patients
Patient Sex Age BMI Age of diagnosis G
1 M 7 yrs 14.57 (Underweight) Birth p
2 M 10 19.80 (Normal weight) Birth p
3 M 12 19.63 (Normal weight) Birth p
4 F 20 16.44 (Underweight) 4 months p
BMI: body mass index.
IRT: immunoreactive trypsinogen, first week/third week after birth. Normal range vafourth patient the diagnosis was suspected during infant
age because of respiratory and gastrointestinal symptoms
and then confirmed by the sweat test. The study was ap-
proved by our local Committee for Clinical Investigation
and informed consent was obtained by each patient or
parent.
Diagnostic tests and clinical data
Sweat chloride concentrations were obtained according to
guidelines by the Gibson a Cooke method [11]. Three tests
were performed in each patient and the mean value is re-
ported. Blood immunoreactive trypsinogen (IRT) was
measured in patients who underwent neonatal screening
for CF (in Italy newborn screening is mandatory since
1998) one and three weeks after birth. Pancreatic insuffi-
ciency was defined as a faecal elastase <200 mg/g faeces.
A quarterly clinical evaluation was performed in our
Centre after the diagnosis. During each visit lung function
(in patients >6 yrs old) was measured according to the
American Thoracic Standard Criteria [12]. Values of
forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) were expressed as % predicted of normal
values adjusted for age, geneder, sex height and weight.
The body mass index (BMI) was used for the clinical def-
inition of the nutritional status according to recommenda-
tions of international consensus [13,14].
Sputum samples for microbiology were obtained for all
adults and adolescents. In younger children who could not
expectorate sputum, oropharyngeal swabs were collected.
Paranasal sinuses and Chest High Resolution Computed
Tomography scan (HRCT) was performed in all pa-
tients to assess the presence of rhino/sinus disease or
bronchiectasis.
The diagnosis of liver disease was considered if at
least one of the following was present in two consecu-
tive evaluations in a period of 6 months: hepatomegaly
(liver edge palpable more than 2 cm below the costal
margin on the mid clavicular line); elevation of alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
gamma-glutamyl transpeptidase (GGT) > 1.5 the normal
value; ultrasound abnormalities consistent with liver in-
volvement according to conventional criteria. Gallbladder
disease was diagnosed if the patient had cholelithiasis or





lues <60 ng/ml and <40 ng/ml third week.
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defined by 2-hour glycemia ≥ 200 mg/dl in the OGTT
or two fasting glycemia measurements greater than
126 mg/dl [16].
Demographic data included in the study were derived
from the last routine evaluation in the Centre. The age
at the diagnosis was derived from the date of the first
sweat test performed.
Genetic analysis
Genotyping of CFTR was carried out on DNA extracted
from blood leucocytes. In our laboratory basic genetic
test was performed by reverse dot blot hybridization by
using INNO-LiPA CFTR19 and CFTR17 + Tn assays
(Innogenetics, Zwiljnaarde, Belgium). The test, performed
according to the recommendation of the supplier, allows
the detection of the 36 more common mutations in
Europe [17]. In patients suspected of CF and a single
allele mutation shown by basic genotyping, advanced
genetic testing is routinely performed in our laboratory.
The p.Leu1077Pro mutation was identified by denaturing
high-performance liquid chromatography (d-HPLC) and
confirmed by gene sequencing analysis with an auto-
mated procedure (Genetic Analyzer, Applied Biosystems).
Methods and procedures for dHPLC and DNA sequen-
cing were reported previously [18,19].
Results
In our Eastern Sicilian Cystic Fibrosis Centre, the preva-
lence of p.Leu1077Pro is 3.6% among all mutations.
All patients had pancreatic insufficiency treated with
enzyme replacement therapy. Patients n.1 and n.4 were
underweight with a BMI of 14.57 and 16.44 respectively
(Table 1). No hepatobiliary disease or diabetes was re-
corded (Table 2).
Both adult and children had recurrent respiratory dis-
ease with some respiratory exacerbations treated with oral
or i.v. antibiotics. Patients n.1 and n.4 had recurrent epi-
sodes of rhinosinusitis. Chest HRCT showed the absence
of bronchiectasis in all patients except in n. 4 (the older of
the group), in which disseminated bilateral bronchiectasis
were present.
In Patients n.1, n.2 and n.3 we found FEV1 and FVC
values within the normal range of predicted, whileTable 2 Clinical data of the patients
Patient FEV1 (%) FVC (%) SaO2 (%) Bronchiectasis Sputum pathog
1 93.2% 91.7% 97% No S. Aureus* P. Aeru
2 89.6% 87.6% 97% No S. Aureus* P. Aeru
3 96% 95% 99% No S. Aureus**
4 55% 52.5% 96% Yes P. Aeruginosa*
*chronically.
**intermittent.patient n.4 showed FEV1 and FVC values below the
normal range. Sputum or throat swab cultures revealed
chronic presence in Patients n.1 and n.2 and episodic
presence in Patient n. 3 of Staphylococcus aureus, while
the occurrence of Pseudomonas aeruginosa in the sputum
was reported few times in patients n.1 and n.2 (success-
fully eradicated by antibiotic treatment) and chronically
from 2005 in Patient n.4 (Table 2). Patients n.1 and n.4
had some episodes of dehydration and hypochloronatre-
mia, particularly during the summer, sometimes so severe
to require hospitalisation.
Discussion
The present study provides evidence that the p.Leu1077-
Pro is a relatively frequent mutation associated with a
phenotype characterized by pathological sweat test, pan-
creatic insufficiency and pulmonary disease.
The p.Leu1077Pro mutation consists in a transition T
to C at nucleotide position 3362 in exon 17b of CFTR
cDNA that is responsible of change of Leucine (CTG) to
Proline (CCG) at position 1077 of the protein. This muta-
tion belongs to the III class CFTR mutations and produce
a protein that is trafficked to the cell membrane but does
not respond to cAMP stimulation [8].
Today it is well known that in 90% of patients there is a
correlation between the general type of CFTR mutation
and the phenotype. Specifically, patients who carry class I-
III mutations on both alleles are associated with pancreatic
exocrine insufficiency, whereas those carrying at least one
class IV-VI CFTR mutation are pancreatic sufficient [3].
Nevertheless p.Leu1077Pro mutation, although belong-
ing to the class III CFTR mutations, was classified by
Bozon et al. [8] in one CF patient, carrying p.Phe508del on
the other chromosome, as a mild genotype because of its
associated pancreatic sufficiency. However, data from
CFTR2 [9] seem to contradict what was claimed by Bozon
et al. since in 78% of patients analyzed in this database
there was pancreatic insufficiency.
Although Cystic Fibrosis is a monogenic disease there
is a great clinical diversity among patients, even among
those carrying the same mutations in the CFTR gene
and the degree of organ involvement and the severity of
the disease seem to be linked not only to the amount of
functional CFTR and to organ’s sensitivity to CFTRens Rhino/sinus disease Pancreatic insufficiency Dehydration
ginosa** Yes Yes Yes
ginosa** No Yes No
No Yes No
Yes Yes Yes
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ground of patient and environmental factors [20,21].
On this regard, the mutation p.Leu1077Pro is typical of
Southern Italy, overall in Puglia, in which the preva-
lence is higher (1.9% among all mutations) than in the
world (< 1%) [10].
In our Eastern Sicilian Cystic Fibrosis Centre its
prevalence resulted even higher (3.6% of all mutations)
compared to that of Puglia. The influence of ethnic
groups of Mediterranean basin and Greek colonisation
of Sicily from 750 BC could explain this difference that
clinically translates into a greater mixture of genomes
within the same territory.
Recently, some modifiers genes, inherited independently
by mutations in the CFTR gene, have been involved in
phenotype/genotype correlation. Some candidate genes
are those involved in the immune response and inflamma-
tion, because their presence or absence could influence
different responses from person to person against bacteria
and viruses responsible for respiratory infection, or could
modulate the affinity of Pseudomonas aeruginosa individ-
ual 's respiratory epithelium [22].
Among our patients, three out of four, who were born
after 1998, were screened for CF. They had abnormal
IRT values and for this reason the CF diagnosis was con-
firmed soon after birth by sweat test. All of them had a
p.Phe508del/p.Leu1077Pro genotype.
In the fourth patient the diagnosis has been performed
during infant age, at 4 months of age: the presence of re-
current respiratory and gastrointestinal symptoms were
the main reasons to address the child to our Centre to
evaluate sweat test which resulted pathological. She had
a p.Asn1303Lys/p.Leu1077Pro genotype.
All 4 patients had a pancreatic insufficiency (PI) pheno-
type and this data, in disagreement with what is reported
by Bozon et al. [8], confirm what is evident from CFTR2.
The presence of both pancreatic insufficiency and
pathological sweat test seem to indicate that this mutation
is responsible for a classical form of CF.
The older patient had several episodes of pneumonia,
Pseudomonas Aeruginosa chronic lung colonization, dis-
seminated bronchiectasis and a significant reduction of
FEV1 and FVC suggesting a severe course of the respira-
tory disease.
In support of this hypothesis, the other three patients,
even if they kept FEV1 and FVC values within normal
range, had showed a few pulmonary exacerbations that
we treated with oral or i.v. antibiotics. Moreover we
found a chronic (in Patients n.1 and n.2) or episodic (in
Patients n.3) colonization of Staphylococcus aureus,
while the occurrence of Pseudomonas aeruginosa in the
sputum was reported few times in patients n.1 and n.2.
In addition, patient n.1 had showed recurrent episodes
of rhinosinusitis.Conclusions
In conclusion, our study seems to confirm the Consensus
Paper [3] and CFTR2 database [9] to the extent that pa-
tients who carry class I-III mutations on both alleles are
associated with pancreatic exocrine insufficiency. How-
ever, given the association with a severe mutation such as
p.Phe508del and p.Asn1303Lys, it is clear that only a
follow-up could allow definitive conclusions on the course
of the pulmonary disease in patients with this genotype/
phenotype profile.
The relatively high prevalence of p.Leu1077Pro associ-
ated with the severe clinical course of the disease in pa-
tients bearing this mutation is of interest for genetic
counselling purposes, as it should be part of mutation
panel to be tested in individuals originated from Southern
Italy.
Competing interests
All the authors certify that there is no conflict of interest with any financial
organization regarding the material discussed in the manuscript.
Authors’ contributions
GFP and SC revised the literature and wrote the manuscript – GFP, GDD and
NR followed the patients in their clinical course. SL conceived the study. MLR
and SL made the final analysis and critical revision of the manuscript. All
authors read and approved the final manuscript.
Acknowledgments
The authors are exceptionally grateful to the families and the patients who
participated in this study.
Received: 6 June 2013 Accepted: 5 November 2013
Published: 13 November 2013
References
1. Riordan JR, Rommens JM, Kerem B, et al: Identification of cystic fibrosis
gene: cloning and characterization of complementary DNA. Science 1989,
254:1066–1073.
2. Cystic Fibrosis Genetic Database. www.genet.sickkids.on.ca/.
3. Castellani C, Cuppens H, Macek MJ, et al: Consensus on the use and
interpretation of cystic fibrosis mutation analysis in clinical practice.
J Cyst Fibros 2008, 7:179–196.
4. Rosenstein BJ, Cutting GR: The diagnosis of cystic fibrosis: a consensus
statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998,
132:589–585.
5. Knowles MR, Durie PR: Whay is cystic fibrosis? N Engl J Med 2002,
347:439–442.
6. De Boeck K, Wilschanski M, Castellani C, et al: Diagnostic working group.
Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006,
61:627–635.
7. Kerem E: Atypical CF, and CF related diseases. Pediatr Respir Rev 2006,
7:S144–S146.
8. Bozon D, Zielenski J, Rininsland F, Tsui LC: Identification of Four New
Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator
Gene: I148T, L1077P, Y1092X, 2183AA→ G. Human Mutation 1994,
3:330–332.
9. Clinical and Functional Translation of CFTR (CFTR2). website.
http://www.cftr2.org/.
10. Castaldo G, Polizzi A, Tomaiuolo R, et al: Comprehensive Cystic Fibrosis
Mutation Epidemiology and Haplotype Characterization in a Southern
Italian Population. Ann Hum Genet 2005, 69:15–24.
11. LeGrys VA, Yankaskas JR, Quittel LM, Marshall BC, Mogayzel PJ Jr: Diagnostic
sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 2007,
151:85–89.
12. American Thoracic S: Standardization of spirometry. 1994 update.
Am J Respir Crit Care Med 1995, 152:1107–1136.
Parisi et al. BMC Research Notes 2013, 6:461 Page 5 of 5
http://www.biomedcentral.com/1756-0500/6/46113. Borowitz D, Baker RD, Stallings V: Consensus report on nutrition for
pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002,
35:246–259.
14. Sinaasappel M, Stern M, Littlewood J, et al: Nutrition in patients with cystic
fibrosis: a European Consensus. J Cyst Fibros 2002, 1:51–75.
15. Williams SG, Evanson JE, Barret N, Hodson ME, Boultbee JE, Westaby D: An
ultrasound scoring system for the diagnosis of liver disease in cystic
fibrosis. J Hepatol 1995, 22:513–521.
16. Moran A, Hardin D, Rodman D, et al: Diagnosis, screening and
management of cystic fibrosis related diabetes mellitus: a consensus
conference report. Diabetes Res Clin Pract 1999, 45:61–73.
17. Chehab FF, Wall J: Detection of multiple cystic fibrosis mutations by
reverse dot blot hybridization: technology for carrier screening.
Hum Genet 1992, 89:163–168.
18. Strom CM, Huang D, Chen C, et al: Extensive sequencing of the cystic
fibrosis transmembrane regulator gene: assay validation and unexpected
benefits of developing a comprehensive test. Genet Med 2003, 5:9–14.
19. McGinniss MJ, Chen C, Redman JB, et al: Extensive sequencing of the CFTR
gene: lessons learned from the first 157 patient samples. Hum Genet
2005, 118:331–338.
20. Zielenski J: Genotype and phenotype in cystic fibrosis. Respiration 2000,
67:117–133.
21. Scriver CR, Waters PJ: Monogenic traits are not simple: lessons from
phenylketonuria. Trend Genet 1999, 15:267–272.
22. Davies J, Alton E, Griesenbach U: Cystic fibrosis modifiers genes.
J R Soc Med 2005, 98:47–54.
doi:10.1186/1756-0500-6-461
Cite this article as: Parisi et al.: Phenotypic expression of the p.Leu1077Pro
CFTR mutation in Sicilian cystic fibrosis patients. BMC Research Notes
2013 6:461.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
